TB-500 Benefits: What the Evidence Shows

The honest answer on TB-500 benefits is that the mechanism is interesting, but the clinical evidence is not there yet. A seven-amino-acid region related to TB-500 has affected cell movement, new-vessel formation and wound repair in laboratory and animal studies. The often-cited heart, eye and human ulcer studies used full-length thymosin beta-4 (Tβ4), not the TB-500 fragment. No controlled human trial shows that systemic TB-500 improves whole-body injury recovery.

That distinction matters more than the number of positive-looking papers. Thymosin beta-4 and TB-500 are related molecules, not interchangeable names for one tested treatment.

TB-500 benefits at a glance

The evidence becomes less transferable at each step from a molecular pathway to a whole-person result. Route matters too: an eye drop or gel applied directly to a wound cannot establish what a systemic injection does.

How actin sequestration connects to cell migration

Full-length Tβ4 binds monomeric G-actin, helping regulate the pool of actin available for a cell to reshape itself. That is relevant to migration because moving cells repeatedly extend, attach and reorganize their internal scaffold. Analytical work identified TB-500 as the N-terminally acetylated 17–23 fragment, Ac-LKKTETQ, of Tβ4 (Esposito et al., Drug Testing and Analysis 2012).

In a separate experiment, the unacetylated seven-amino-acid LKKTETQ motif produced activity similar to full-length Tβ4 at about 50 nM in endothelial-cell migration and chick aortic-arch sprouting assays (Philp et al., FASEB Journal 2003). That is direct evidence for biological activity in the sequence region. It is not a human outcome study, and the test peptide was not the exact acetylated TB-500 drug substance.

Angiogenesis is a mechanism, not a promised outcome

Angiogenesis means forming new blood vessels. It is part of normal tissue repair because healing tissue needs oxygen and nutrients. The same Philp study found that the seven-amino-acid motif supported endothelial migration and vessel sprouting outside a living human body. This explains why angiogenesis appears on a TB-500 benefits map; it does not show that giving TB-500 to a person produces useful, controlled blood-vessel growth or faster recovery.

What the wound studies add

In aged mice, full-length Tβ4 increased measures including keratinocyte migration, wound contraction and collagen deposition. An unacetylated LKKTETQ peptide also promoted repair in the aged-animal model at a level comparable to the parent molecule (Philp et al., Wound Repair and Regeneration 2003). This is the closest preclinical bridge from the actin-binding motif to wound repair, but it remains an animal result with a related, not identical, peptide.

Combining TB-500 with BPC-157 does not create human evidence for either component. The Wolverine peptide stack explains why they are paired; each benefit claim still has to stand on its own research.

The cardiac work used full-length Tβ4 in mice

The landmark Nature paper is important and frequently overextended. Bock-Marquette and colleagues gave full-length Tβ4 after coronary-artery ligation in mice. They reported increased ILK and Akt activity, better early heart-cell survival and improved cardiac function (Bock-Marquette et al., Nature 2004).

That study supports a cardiac-repair pathway for Tβ4 in a mouse injury model. It did not test TB-500, did not enroll people and does not establish a cardiac benefit from systemic peptide treatment in clinical practice.

What the human Tβ4 trials found

The human efficacy evidence for healing is local and belongs to full-length Tβ4 formulations. In a nine-patient phase 2 severe-dry-eye trial, 0.1% RGN-259 eye drops produced signals in discomfort and corneal staining (Sosne et al., Cornea 2015). A later neurotrophic-keratopathy study enrolled 18 people: complete healing at four weeks occurred in 6 of 10 Tβ4-treated participants and 1 of 8 placebo participants, but that comparison did not reach statistical significance at the primary time point (Sosne et al., International Journal of Molecular Sciences 2022).

Full-length Tβ4 has also undergone intravenous phase 1 safety and pharmacokinetic testing in 40 healthy volunteers. That trial did not test healing efficacy and still studied a different molecule from TB-500 (Crockford et al., Annals of the New York Academy of Sciences 2010).

A completed phase 2 pressure-ulcer trial enrolled 72 people and tested topical full-length Tβ4 for up to 84 days, with wound healing as a secondary outcome (ClinicalTrials.gov NCT00382174). In a separate 73-person venous-stasis-ulcer trial, topical Tβ4 had safety findings comparable to placebo and a possible efficacy signal at one concentration; the authors said about 25% of selected patients could achieve complete healing within three months (Guarnera et al., Annals of the New York Academy of Sciences 2010).

These trials show that full-length Tβ4 has reached human testing. They do not validate injected TB-500 for systemic recovery, and the efficacy studies' local routes and small samples limit what can be inferred.

What has not been shown

There is no controlled human evidence that systemic TB-500 speeds muscle, tendon or ligament recovery, shortens return-to-activity time, or improves cardiac repair. FDA's 2026 scientific briefing likewise said it had not identified human data for TB-500 by any route and found the nonclinical evidence insufficient to support wound healing (FDA TB-500 briefing, July 2026).

For the separate injury discussion, see TB-500 and injury recovery. Questions about tolerability belong with the TB-500 side-effects guide, where the absence of robust human safety data is part of the answer.

Where a prescription review fits

As of September 2026, FDA's July advisory-committee review of TB-500 concerned possible inclusion on the 503A bulks list, not proof of benefit; advisory recommendations are non-binding (FDA meeting record). Regulatory status is one input, and a licensed provider may still prescribe a compounded formulation when they judge it appropriate; that decision belongs to the patient and doctor.

At Promise, a licensed provider reviews every request, and not everyone qualifies. The point of that gate is accountable judgment in a field where the evidence has real gaps.